MX2022000718A - Vacuna en vector recombinante de adenovirus aviar serotipo 9. - Google Patents
Vacuna en vector recombinante de adenovirus aviar serotipo 9.Info
- Publication number
- MX2022000718A MX2022000718A MX2022000718A MX2022000718A MX2022000718A MX 2022000718 A MX2022000718 A MX 2022000718A MX 2022000718 A MX2022000718 A MX 2022000718A MX 2022000718 A MX2022000718 A MX 2022000718A MX 2022000718 A MX2022000718 A MX 2022000718A
- Authority
- MX
- Mexico
- Prior art keywords
- vaccine
- recombinant
- disease
- adenovirus vector
- avian adenovirus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10241—Use of virus, viral particle or viral elements as a vector
- C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10271—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
Abstract
Se describe una vacuna recombinante que comprende un vector de adenovirus aviar serotipo 9 (FAdV-9) que tiene insertada por lo menos una secuencia de nucleótidos exógena que codifica para por lo menos un antígeno de una enfermedad de interés y que reemplaza la región no esencial del genoma del adenovirus, y un vehículo, adyuvante y/o excipiente farmacéuticamente aceptable, en donde la por lo menos una secuencia de nucleótidos exógena que codifica para por lo menos un antígeno de una enfermedad de interés y que reemplaza la región no esencial del genoma del adenovirus se localiza entre los nucleótidos 491-2782; el vector de esta vacuna es estable para producción a escala industrial; asimismo, aún cuando esta vacuna se administra en combinación con una vacuna contra la enfermedad de Marek, ambas producen una respuesta inmune adecuada que no se ve afectada por la interferencia entre ellas; de la misma manera, la efectividad de la vacuna recombinante no se ve afectada por los anticuerpos maternos, y es capaz de inducir una respuesta protectora tanto temprana como duradera, aún con una sola aplicación.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2014/063809 WO2016020730A1 (es) | 2014-08-08 | 2014-08-08 | Vacuna en vector recombinante de adenovirus aviar serotipo 9 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022000718A true MX2022000718A (es) | 2022-02-24 |
Family
ID=55263220
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017001742A MX2017001742A (es) | 2014-08-08 | 2015-08-06 | Vacuna en vector recombinante de adenovirus aviar serotipo 9. |
MX2022000718A MX2022000718A (es) | 2014-08-08 | 2017-02-07 | Vacuna en vector recombinante de adenovirus aviar serotipo 9. |
MX2022003590A MX2022003590A (es) | 2014-08-08 | 2017-02-07 | Vacuna en vector recombinante de adenovirus aviar serotipo 9. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017001742A MX2017001742A (es) | 2014-08-08 | 2015-08-06 | Vacuna en vector recombinante de adenovirus aviar serotipo 9. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022003590A MX2022003590A (es) | 2014-08-08 | 2017-02-07 | Vacuna en vector recombinante de adenovirus aviar serotipo 9. |
Country Status (14)
Country | Link |
---|---|
US (1) | US10758608B2 (es) |
EP (1) | EP3178938A4 (es) |
JP (1) | JP2017526737A (es) |
KR (1) | KR20170063552A (es) |
CN (1) | CN106661592A (es) |
AR (1) | AR101468A1 (es) |
BR (1) | BR112017002577A2 (es) |
CA (1) | CA2956997A1 (es) |
CO (1) | CO2017001614A2 (es) |
EA (1) | EA038951B1 (es) |
MX (3) | MX2017001742A (es) |
PE (2) | PE20221792A1 (es) |
PH (1) | PH12017500216A1 (es) |
WO (2) | WO2016020730A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107037526A (zh) | 2008-08-08 | 2017-08-11 | 3M创新有限公司 | 具有粘弹性层的用于控制光的光导 |
WO2016020730A1 (es) * | 2014-08-08 | 2016-02-11 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna en vector recombinante de adenovirus aviar serotipo 9 |
CN108126191B (zh) * | 2016-12-01 | 2021-04-06 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
CN108653724B (zh) * | 2017-04-01 | 2020-11-27 | 普莱柯生物工程股份有限公司 | 一种用于预防禽减蛋综合征的疫苗组合物、及其制备方法和应用 |
CN110680914B (zh) * | 2019-09-23 | 2021-11-26 | 洛阳职业技术学院 | 一种三联灭活疫苗及其制备方法 |
CN111494617A (zh) * | 2020-04-08 | 2020-08-07 | 扬州优邦生物药品有限公司 | 一种四联灭活疫苗及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL103939A (en) * | 1992-12-01 | 1996-09-12 | Abic Ltd | An anti-DBI vaccine in birds containing attenuated live DBI virus |
JP3606870B2 (ja) | 1993-04-14 | 2005-01-05 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション | 組換えトリアデノウイルスベクター |
US6296852B1 (en) * | 1993-04-14 | 2001-10-02 | Commonwealth Scientific And Industrial Research Organisation | Recombinant avian adenovirus vector |
US6048535A (en) * | 1997-06-12 | 2000-04-11 | Regents Of The University Of Minnesota | Multivalent in ovo avian vaccine |
US20100003279A1 (en) * | 2005-12-22 | 2010-01-07 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Vaccine for in ovo inoculation |
JP2012504140A (ja) * | 2008-09-26 | 2012-02-16 | オーバーン・ユニバーシティ | 非複製性ベクターワクチンの粘膜投与による鳥類の免疫処置 |
CN102281896A (zh) * | 2008-11-19 | 2011-12-14 | 阿维-梅克斯实验室公司 | 重组失活病毒载体疫苗 |
WO2016020730A1 (es) * | 2014-08-08 | 2016-02-11 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna en vector recombinante de adenovirus aviar serotipo 9 |
MX2018000353A (es) * | 2015-07-10 | 2018-03-14 | Univ Guelph | Sistema vector de adenovirus aviar 9 (fadv-9) y metodos asociados. |
-
2014
- 2014-08-08 WO PCT/IB2014/063809 patent/WO2016020730A1/es active Application Filing
-
2015
- 2015-08-06 US US15/502,443 patent/US10758608B2/en active Active
- 2015-08-06 CN CN201580042608.3A patent/CN106661592A/zh active Pending
- 2015-08-06 CA CA2956997A patent/CA2956997A1/en active Pending
- 2015-08-06 KR KR1020177006378A patent/KR20170063552A/ko not_active IP Right Cessation
- 2015-08-06 EA EA201790296A patent/EA038951B1/ru unknown
- 2015-08-06 BR BR112017002577-9A patent/BR112017002577A2/pt active Search and Examination
- 2015-08-06 EP EP15829016.3A patent/EP3178938A4/en not_active Withdrawn
- 2015-08-06 JP JP2017526775A patent/JP2017526737A/ja active Pending
- 2015-08-06 MX MX2017001742A patent/MX2017001742A/es unknown
- 2015-08-06 PE PE2022001034A patent/PE20221792A1/es unknown
- 2015-08-06 PE PE2017000180A patent/PE20170429A1/es unknown
- 2015-08-06 WO PCT/IB2015/055994 patent/WO2016020885A1/es active Application Filing
- 2015-08-07 AR ARP150102532A patent/AR101468A1/es active IP Right Grant
-
2017
- 2017-02-03 PH PH12017500216A patent/PH12017500216A1/en unknown
- 2017-02-07 MX MX2022000718A patent/MX2022000718A/es unknown
- 2017-02-07 MX MX2022003590A patent/MX2022003590A/es unknown
- 2017-02-20 CO CONC2017/0001614A patent/CO2017001614A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2016020885A1 (es) | 2016-02-11 |
PH12017500216B1 (en) | 2017-07-03 |
AR101468A1 (es) | 2016-12-21 |
CN106661592A (zh) | 2017-05-10 |
BR112017002577A2 (pt) | 2018-02-27 |
US10758608B2 (en) | 2020-09-01 |
KR20170063552A (ko) | 2017-06-08 |
EA038951B1 (ru) | 2021-11-15 |
MX2017001742A (es) | 2017-05-15 |
EP3178938A4 (en) | 2018-03-21 |
CO2017001614A2 (es) | 2017-07-28 |
PE20170429A1 (es) | 2017-05-11 |
US20170232096A1 (en) | 2017-08-17 |
EA201790296A1 (ru) | 2017-06-30 |
PH12017500216A1 (en) | 2017-07-03 |
WO2016020730A1 (es) | 2016-02-11 |
JP2017526737A (ja) | 2017-09-14 |
PE20221792A1 (es) | 2022-11-25 |
EP3178938A1 (en) | 2017-06-14 |
CA2956997A1 (en) | 2016-02-11 |
MX2022003590A (es) | 2022-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022003590A (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9. | |
EP4104854A3 (en) | Multivalent vaccines for rabies virus and coronaviruses | |
WO2015142671A3 (en) | Influenza virus vectors and uses therefor | |
MX2014006361A (es) | Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos. | |
WO2011106607A3 (en) | Subunit vaccines for herpes viruses and methods of use | |
MX2022002106A (es) | Formulaciones de vacuna de vial unico. | |
WO2015134368A3 (en) | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
MX2018015361A (es) | Formulacion de vacuna contra el vih. | |
MX2022006602A (es) | Vacunas de herpesvirus de pavo recombinante y uso de las mismas. | |
MY189495A (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
WO2016191641A3 (en) | Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens | |
MX2010006984A (es) | Vacunas contra la malaria. | |
AU2014232363A8 (en) | Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom | |
MX2020002810A (es) | Composicion inmunogenica de citomegalovirus humano. | |
MY189501A (en) | Pestivirus vaccines for congenital tremors | |
EA201890274A1 (ru) | Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы | |
MX2019007924A (es) | Vacunas contra la influenza. | |
MX358507B (es) | Antigenos vacunales quimericos contra el virus de la hepatitis c. | |
WO2015041924A8 (en) | Recombinant respiratory syncytial virus (rsv) and vaccines | |
TN2014000393A1 (en) | Modified marek's disease virus, and vaccines made therefrom | |
CA3045626A1 (en) | Bovine herpesvirus type 1 (bohv-1) vector against bovine respiratory disease complex | |
PH12017500407A1 (en) | Streptococcus agalactiae antigens associated with strains virulent in fish | |
WO2015070207A3 (en) | Ama-1 epitopes, antibodies, compositions, and methods of making and using the same | |
WO2020071869A8 (ko) | 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도 | |
TH156282A (th) | ไวรัสโรคมาเร็กซ์ที่ถูกดัดแปลงและวัคซีนที่ทำจากมัน |